Precigen, Inc. $PGEN reported a sharp year-over-year jump in second-quarter revenue, with sales rising to $55.0 million, well above the analyst estimate of about $28.4 million. The company also posted gross profit of $52.2 million, reflecting strong top-line growth in the period.
Profitability was also ahead of expectations, with diluted earnings per share of $0.05 versus an estimated loss of $0.01. Net income attributable to common shareholders came in at $20.1 million, while operating profit reached $22.6 million.
On the cash flow and balance sheet side, operating cash flow was a use of $17.8 million, while cash and cash equivalents stood at $16.3 million. Total liabilities were $126.7 million, and capital spending remained limited at $392,000.
Investors responded positively to the release, with the stock rising 13.1% since the market close.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Precigen, Inc. Insider Trading Activity
Precigen, Inc. insiders have traded $PGEN stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $PGEN stock by insiders over the last 6 months:
- RANDAL J KIRK has made 0 purchases and 11 sales selling 4,772,781 shares for an estimated $15,750,177.
- HELEN SABZEVARI (President and CEO) has made 0 purchases and 2 sales selling 466,086 shares for an estimated $2,562,794.
- HARRY JR. THOMASIAN (Chief Financial Officer) has made 0 purchases and 4 sales selling 341,884 shares for an estimated $1,901,756.
- RUTUL R SHAH (Chief Operating Officer) has made 0 purchases and 3 sales selling 119,399 shares for an estimated $656,808.
- PHIL TENNANT (Chief Commercial Officer) sold 30,272 shares for an estimated $131,985
- DONALD P. LEHR (Chief Legal Officer) sold 29,131 shares for an estimated $127,011
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Precigen, Inc. Hedge Fund Activity
We have seen 91 institutional investors add shares of Precigen, Inc. stock to their portfolio, and 65 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 7,079,780 shares (-51.6%) from their portfolio in Q1 2026, for an estimated $27,398,748
- DIAMETRIC CAPITAL, LP added 2,954,764 shares (+76.8%) to their portfolio in Q1 2026, for an estimated $11,434,936
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 2,807,901 shares (-78.0%) from their portfolio in Q1 2026, for an estimated $10,866,576
- FMR LLC removed 2,653,583 shares (-57.0%) from their portfolio in Q1 2026, for an estimated $10,269,366
- FRANKLIN RESOURCES INC added 2,165,742 shares (+462.7%) to their portfolio in Q1 2026, for an estimated $8,381,421
- BOXER CAPITAL MANAGEMENT, LLC added 2,125,000 shares (+154.5%) to their portfolio in Q1 2026, for an estimated $8,223,750
- JANE STREET GROUP, LLC added 1,821,790 shares (+inf%) to their portfolio in Q1 2026, for an estimated $7,050,327
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Precigen, Inc. Price Targets
Multiple analysts have issued price targets for $PGEN recently. We have seen 2 analysts offer price targets for $PGEN in the last 6 months, with a median target of $12.5.
Here are some recent targets:
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $14.0 on 05/28/2026
- Jason N. Butler from Citizens set a target price of $11.0 on 05/14/2026
